20180502 MISE A DISPO AG – US
Category: Press release
€35.6 Million in Cash and Cash Equivalents as of March 31, 2018
20180426-Resultats-Q1-2018-EN
Transgene Presents Data on a Novel Viral Vector with Remarkable Anticancer Activity at AACR 2018
20180418 AACR 2018 poster PCPV – EN
Transgene to announce major clinical results in 2018 and achieve promising progress on its new oncolytic viruses
20180321-Resultats-2017-EN
Transgene to Present Data on a Novel Viral Vector with Superior Anti-Cancer Immunotherapeutic Activity at AACR 2018
20180315 PR AACR LB poster accepted
First Chronic Hepatitis B Patient Dosed in China in a Phase 1 Trial of T101 (Transgene’s TG1050 Technology)
20180117 PR FPI T101
First Patient Dosed in a Phase 2 Trial with Transgene’s TG4010 + Nivolumab + Chemotherapy for the First-Line Treatment of Lung Cancer (NSCLC)
20180116 PR FPI TG4010 1L EN
Transgene Announces Financial Calendar for 2018
20171221 Financial calendar 2018 EN
Transgene Announces Upcoming Investor Meetings
20171218 PR financial agenda T1 18
BioInvent and Transgene collaborate on next generation oncolytic viruses encoding an anti-CTLA-4 antibody to treat solid tumors
BioInvent and Transgene collaborate on next generation oncolytic viruses encoding an anti-CTLA-4 antibody to treat solid tumors